Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers.

We sought to elucidate the prognostic impact of the SARC-F score among patients with gastrointestinal advanced malignancies ( = 421). A SARC-F score ≥ 4 was judged to have a strong suspicion for sarcopenia. In patients with ECOG-PS 4 ( = 43), 3 ( = 61), and 0-2 ( = 317), 42 (97.7%), 53 (86.9%) and 8 (2.5%) had the SARC-F score ≥ 4. During the follow-up period, 145 patients (34.4%) died. All deaths were cancer-related. The 1-year cumulative overall survival (OS) rate in patients with SARC-F ≥ 4 ( = 103) and SARC-F < 4 ( = 318) was 33.9% and 61.6% ( < 0.0001). In the multivariate analysis for the OS, total lymphocyte count ≥ 1081/μL ( = 0.0014), the SARC-F score ≥ 4 ( = 0.0096), Glasgow prognostic score (GPS) 1 ( = 0.0147, GPS 0 as a standard), GPS 2 ( < 0.0001, GPS 0 as a standard), ECOG-PS 2 ( < 0.0001, ECOG-PS 0 as a standard), ECOG-PS 3 ( < 0.0001, ECOG-PS 0 as a standard), and ECOG-PS 4 ( < 0.0001, ECOG-PS 0 as a standard) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and best cutoff point of the SARC-F score was two. In conclusion, the SARC-F score is useful in patients with gastrointestinal advanced malignancies.